NCT00656734View on ClinicalTrials.gov

Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Kidney Cancer
Interventions
BIOLOGICAL

MDX 1411

MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10466

Montefiore Medical Center, The Bronx

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

48201

Barbara Ann Karmanos Cancer Institute, Detroit

89135

Nevada Cancer Institute, Las Vegas

97213

Providence Portland Medical Center, Portland

02215

Beth Israel Deaconness Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY